HROW
HROW
NASDAQ · Pharmaceuticals

Harrow Inc

$34.20
+0.28 (+0.83%)
As of Sep 22, 1:40 PM ET ·
Financial Highlights (FY 2026)
Revenue
281.08M
Net Income
-5,304,850
Gross Margin
75.0%
Profit Margin
-1.9%
Rev Growth
+45.4%
D/E Ratio
4.64
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 75.0% 75.0% 63.9% 63.9%
Operating Margin 8.4% 7.5% 23.6% 21.0%
Profit Margin -1.9% -1.8% 15.6% 16.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 281.08M 193.33M 753.50M 775.29M
Gross Profit 210.95M 145.10M 481.22M 495.14M
Operating Income 23.50M 14.55M 178.06M 162.96M
Net Income -5,304,850 -3,283,833 117.60M 129.68M
Gross Margin 75.0% 75.0% 63.9% 63.9%
Operating Margin 8.4% 7.5% 23.6% 21.0%
Profit Margin -1.9% -1.8% 15.6% 16.7%
Rev Growth +45.4% +45.4% +23.8% +22.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 510.82M 510.82M 692.61M 691.25M
Total Equity 110.17M 110.17M 1.12B 1.10B
D/E Ratio 4.64 4.64 0.62 0.63
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 25.48M 16.65M 185.25M 214.55M
Free Cash Flow 80.89M 86.69M